Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 161Neoplasm Metastasis 27Neoplasms 25Breast Neoplasms, Male 15Brain Neoplasms 14Head and Neck Neoplasms 8Urinary Bladder Neoplasms 7Stomach Neoplasms 7Squamous Cell Carcinoma of Head and Neck 6Ovarian Neoplasms 6Colorectal Neoplasms 6Prostatic Neoplasms 5Inflammatory Breast Neoplasms 5Glioblastoma 5Carcinoma, Non-Small-Cell Lung 5Esophageal Neoplasms 4Carcinoma, Ovarian Epithelial 4Unspecified Adult Solid Tumor, Protocol Specific 3Salivary Gland Neoplasms 3Recurrence 3Pancreatic Neoplasms 3Lung Neoplasms 3Gliosarcoma 3Glioma 3Gallbladder Neoplasms 3Ependymoma 3Carcinoma, Squamous Cell 3Triple Negative Breast Neoplasms 2Solid Tumors 2Osteitis Deformans 2

Interventions

Radiotherapy 1Oxaliplatin 1Lapatinib 1Fluorouracil 1Combined Modality Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × HER2 Positive Esophagogastric Cancer × Lapatinib × Clear all
NCT01769508 2016-06-13

Study of 5-FU, Oxaliplatin, & Lapatinib Combined With Radiation Therapy to Treat HER2 Positive Esophagogastric Cancer

SCRI Development Innovations, LLC

Phase 2 Terminated
12 enrolled 8 charts
Gastrointestinal

HER2 Positive Esophagogastric Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡